Dementia SomaSignal TestBiomarker1 paperHuman trial1LatestNov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 01 in 12 monthsAlzheimer's & Dementia·9 AugSemaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trialRandomised trial in 2,970 peopleSemaglutidePaper
Alzheimer's & Dementia·9 AugSemaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trialRandomised trial in 2,970 peopleSemaglutidePaper